Inovio shares dive on cervical cancer vax speculation

Shares of Inovio Pharmaceuticals ($INO) took a hit Tuesday on rumors that CEO Joseph Kim was "walking back expectations" for a Phase II study of DNA vaccine candidate VGX-3100 in women with cervical precancerous lesions. As TheStreet's Adam Feuerstein theorized, the company already has the data--and they don't look so good. "Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?" he asked. That question sent shares spiraling downward 13.36%, but Inovio refuted the claim. "There exists the prospect that our immunotherapy approach may eliminate the presence of HPV virus to minimize future recurrences," it said in a statement Wednesday. Report | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.